Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNAT
CUSIPN/A
Phone858-376-2600
Debt
Debt-to-Equity Ratio0.57
Current Ratio2.41
Quick Ratio2.41
Price-To-Earnings
Trailing P/E Ratio-8.15
Forward P/E Ratio-7.31
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.38 million
Price / Sales4.22
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book5.34
Profitability
EPS (Most Recent Fiscal Year)($0.61)
Net Income$-17,390,000.00
Net Margins-49.30%
Return on Equity-64.30%
Return on Assets-21.67%
Miscellaneous
Employees35
Outstanding Shares30,060,000
Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions
What is Conatus Pharmaceuticals' stock symbol?
Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."
How were Conatus Pharmaceuticals' earnings last quarter?
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.17) EPS for the quarter, hitting analysts' consensus estimates of ($0.17). The biotechnology company had revenue of $9.74 million for the quarter, compared to analyst estimates of $8.88 million. Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%. View Conatus Pharmaceuticals' Earnings History.
When is Conatus Pharmaceuticals' next earnings date?
What price target have analysts set for CNAT?
6 analysts have issued 1-year price targets for Conatus Pharmaceuticals' stock. Their predictions range from $4.30 to $20.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $12.1414 in the next twelve months. View Analyst Ratings for Conatus Pharmaceuticals.
Who are some of Conatus Pharmaceuticals' key competitors?
Some companies that are related to Conatus Pharmaceuticals include Prothena (PRTA), Beyondspring (BYSI), ChemoCentryx (CCXI), Achaogen (AKAO), Cara Therapeutics (CARA), Obseva (OBSV), Viking Therapeutics (VKTX), TIGENIX/S (TIG), Lannett (LCI), AC Immune (ACIU), Rigel Pharmaceuticals (RIGL), Stemline Therapeutics (STML), Zymeworks (ZYME), Merus (MRUS) and Aurinia Pharmaceuticals (AUPH).
Who are Conatus Pharmaceuticals' key executives?
Conatus Pharmaceuticals' management team includes the folowing people:
- Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 66)
- Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 50)
- Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 63)
- Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 60)
- Mr. Daniel L. Ripley, Sr. VP of Bus. Devel., Program & Alliance Management (Age 57)
Has Conatus Pharmaceuticals been receiving favorable news coverage?
News articles about CNAT stock have trended positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a coverage optimism score of 0.42 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Conatus Pharmaceuticals' major shareholders?
Conatus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include MPM Asset Management LLC (8.20%), BlackRock Inc. (7.71%), Millennium Management LLC (1.19%), American Century Companies Inc. (0.36%), Alambic Investment Management L.P. (0.29%) and JPMorgan Chase & Co. (0.25%). View Institutional Ownership Trends for Conatus Pharmaceuticals.
Which institutional investors are selling Conatus Pharmaceuticals stock?
Which institutional investors are buying Conatus Pharmaceuticals stock?
CNAT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., MPM Asset Management LLC, American Century Companies Inc., JPMorgan Chase & Co., Wells Fargo & Company MN and The Manufacturers Life Insurance Company . View Insider Buying and Selling for Conatus Pharmaceuticals.
How do I buy shares of Conatus Pharmaceuticals?
Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Conatus Pharmaceuticals' stock price today?
One share of CNAT stock can currently be purchased for approximately $4.97.
How big of a company is Conatus Pharmaceuticals?
Conatus Pharmaceuticals has a market capitalization of $150.02 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.
How can I contact Conatus Pharmaceuticals?
Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]
MarketBeat Community Rating for Conatus Pharmaceuticals (CNAT)
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
